Dogwood Therapeutics DWTX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's other income, net (note 6)?
- Dogwood Therapeutics (DWTX) reported other income, net (note 6) of $90.95K in Q1 2026.
- How has Dogwood Therapeutics's other income, net (note 6) changed year-over-year?
- Dogwood Therapeutics's other income, net (note 6) increased by 101.4% year-over-year, from -$6.3M to $90.95K.
- What is the long-term trend for Dogwood Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Dogwood Therapeutics's other income, net (note 6) has grown at a 109.3% compound annual growth rate (CAGR), from -$319.33K to -$6.13M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.